Emerging Perioperative Treatment Using Immune Checkpoint Inhibitors in Patients with Resectable NSCLC
Webinar | English, Japanese | 1 Hr 01 Min
Image For Activity Cover
Availability
On-Demand
Cost
$0.00
Credit Offered
No Credit Offered
Immune checkpoint inhibitors and EGFR-TKIs, which have shown efficacy in advanced lung cancer, are now being applied to perioperative treatment. Many agents are expected to be introduced into the perioperative treatment of resectable Stage IB to Stage III, but the balance of efficacy and adverse events varies for each subset of patients. In using each agent in clinical practice, the debate continues as to whether a new perioperative therapy should be recommended for all patients or for a subset of patients. In this webinar, we would like to deepen the discussion on immune checkpoint inhibitors in the perioperative setting.

This is the joint webinar between IASLC and JLCS (Japan Lung Cancer Society, https://www.haigan.gr.jp/). This webinar will consist of a 20-minute presentation from the keynote speaker, Dr. Enriqueta Felip, given in English, followed by a 25-minute panel discussion conducted in Japanese with 15-minutes at the end for Q&A. This webinar is designed to meet the educational needs of physicians and researchers specializing in medical oncology, thoracic surgery, and radiation oncology. To meet the needs of both international and Japanese audiences, the keynote will be provided in English and the panel discussion in Japanese.
This webinar is designed to meet the educational needs of physicians and researchers specializing in medical oncology, thoracic surgery, and radiation oncology.
Upon completion of this activity, the participants should be able to:
  • Understand current standards of perioperative treatment in resectable NSCLC
  • Understand candidates for future standard therapy of perioperative treatment
  • Discuss appropriate indication of perioperative treatment including immune checkpoint inhibitors
  • Hidehito Horinouchi, MD, PhD, Assistant Chief of the Department of Thoracic Oncology, National Cancer Center Hospital
  • Yasuhiro Tsutatni, MD, PhD, Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine Hiroshima University

The information presented is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

If you need assistance with this activity, please email: education@iaslc.org.
Powered By